申请人:Triad National Security, LLC
公开号:US20200109173A1
公开(公告)日:2020-04-09
The present disclosure provides peptoid-based chelating ligands, corresponding cyclic peptoids, and methods of making thereof. Functional groups may be tailored for high metal binding affinity and selectivity. The side chains of a cyclic peptoid according to the present disclosure may be selected based on, for example, high affinity for actinide or other metal ions, selectivity for actinide or other metal ions, the ability to recover a metal once it is bound to the peptoid, and whether the overall peptoid should be hydrophobic or hydrophilic. Unlike siderophores, peptoid-based chelating ligands of the present disclosure are not readily hydrolyzed under physiological conditions. Therefore, peptoid-based chelating ligands may be, for example, used to treat actinide (e.g., iron and lead) poisoning in vivo. Moreover, peptoid-based chelating ligands of the present disclosure may be used for medical imaging, chelation therapy, drug delivery, and separation technologies, for example.
本公开提供基于肽酰胺的螯合配体、相应的环状肽酰胺及其制备方法。功能基团可以根据高金属结合亲和力和选择性进行定制。根据本公开的环状肽酰胺的侧链可以根据,例如,对锕系元素或其他金属离子的高亲和力、对锕系元素或其他金属离子的选择性、一旦金属与肽酰胺结合后是否能够回收金属,以及整体肽酰胺是疏水性还是亲水性来进行选择。与铁载体不同,本公开的基于肽酰胺的螯合配体在生理条件下不容易水解。因此,基于肽酰胺的螯合配体可以用于治疗体内的锕系元素(例如铁和铅)中毒。此外,本公开的基于肽酰胺的螯合配体可以用于医学成像、螯合疗法、药物输送和分离技术等领域。